FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361028650> ?p ?o ?g. }

• W4361028650 endingPage "172" @default.
• W4361028650 startingPage "169" @default.
• W4361028650 abstract "The use of steroids remains the proven standard of care for renal transplant patients. Its use has been associated with a myriad of metabolic adverse effects (well known to the reader), which, in turn, has motivated many transplant patients to request their discontinuation. Despite the initial encouraging news from small, single-center studies, the largest prospective, randomized, long-term (>5 years) trial to date failed to show a significant metabolic benefit from steroid avoidance/minimization (1). In addition, steroid withdrawal studies have been characterized by a high incidence of biopsy-confirmed mild acute rejection (Banff 1a and 1b). These findings have been more pronounced in patients at high immunologic risk (e.g., the young; patients of black race) and are primarily seen with delayed and slow steroid tapers (carried out >6 months from the time of transplantation). As a result of this experience and the introduction of more potent immunosuppressants such as antithymocyte globulin, anti-CD25 antibodies (daclizumab and basiliximab), and anti-CD52 antibodies (alemtuzumab), slow steroid withdrawal protocols have been replaced by protocols in which steroids are minimized or avoided. The avoidance protocols in particular are characterized by either no corticosteroid therapy or the full elimination of steroids within 7 days of transplantation. A recent US analysis from the Scientific Registry of Transplant Recipients concluded that patients who are on steroid avoidance therapies do not have a worse outcome compared with patients who are on maintenance steroids regimens (2). A recent discussion of this retrospective analysis concluded that despite a possible selection bias, the findings were indicative that patients could be safely discharged on a steroid-free regimen (3). The development of interstitial fibrosis and tubular atrophy (so-called chronic allograft nephropathy) and a higher incidence of more severe rejection (Banff 2a) has been identified in long-term avoidance steroid studies (1). In some cases, it may take as long as 5 years to see renal allograft function impairment in patients who receive a steroid avoidance regimen (4). The aim of the study by Schold et al. was to determine which factors are associated with the failure of transplant patients to remain free of steroid therapy 6 months after transplantation. They used multivariate logistic regression and Kaplan-Meier and Cox proportional hazard models to evaluate patient and graft survival from deceased- and living-donor recipients. In their study of >80,000 patients, they categorized the transplant recipients into three groups (N = 84,647): (1) Patients who received steroids uninterruptedly after transplantation (n = 60,429 [71%]), (2) patients who received no steroids since transplantation (n = 18,591 [22%]), and (3) patients who were started on steroids after a 6-month steroid-free period (n = 5627 [7%]). They obtained their information from the Scientific Registry of Transplant Recipients data system focusing on the period from 2002 through 2008. Findings. Patients who remained steroid-free were more likely to be characterized as having low immunologic risk (e.g., living-donor transplant recipients, white patients, unsensitized, primary transplant recipient). Among the risk factors implicated in the resumption of steroids among deceased-donor recipients were black race, high sensitization, HLA mismatching, retransplantation, and recipients of organs from older donors; these patients were identified as having high immunologic risk. A similar trend was observed for living-donor recipients who resumed steroids 1 year after transplantation, in which factors including donor age >60 years, high sensitization, less preemptive transplantation, greater likelihood of an unrelated donor, increased HLA mismatching, and retransplants were noted. Graft survival was not different between the steroid avoidance group and those who were maintained on corticosteroids (adjusted hazard ratio [AHR] 1.01; 95% confidence interval [CI] 0.96 to 1.07). Conversely, the need to resume steroid therapy was clearly detrimental to the outcome of the renal allograft (AHR 1.20; 95% CI 1.11 to 1.29) and to patient survival (AHR 1.17; 95% CI 1.06 to 1.29). There was no statistical difference between deceased-donor and living-donor recipients. Induction therapy with alemtuzumab and the use of tacrolimus were associated with a lesser need for initiation of steroids at 6 months. Lastly, there was a suggestion (P < 0.001) of a center effect regarding the use of a steroid-free protocol and resumption of steroid therapy. Commentary. The introduction of more potent immunosuppressive agents (anti-thymocyte globulin, alemtuzumab, tacrolimus) has facilitated the long-sought development of steroid-free/minimization regimens; however, this management approach should be individualized. On the basis of the study findings of Schold et al., until the long-term safety and efficacy of steroid minimization strategies are validated (by controlled clinical trials with adequate long-term follow-up), the use of steroid avoidance/minimization protocols in patients at high immunologic risk—characterized by black race, a high degree of sensitization (panel-reactive antibody >30%), HLA mismatching, retransplants, and organs from older donors—should be discouraged." @default.
• W4361028650 created "2023-03-30" @default.
• W4361028650 creator A5059400966 @default.
• W4361028650 creator A5061287999 @default.
• W4361028650 creator A5075099729 @default.
• W4361028650 creator A5085054297 @default.
• W4361028650 creator A5087164252 @default.
• W4361028650 date "2010-02-01" @default.
• W4361028650 modified "2023-10-16" @default.
• W4361028650 title "Sizzling Issues in Clinical Renal Transplantation" @default.
• W4361028650 cites W2026860062 @default.
• W4361028650 cites W2062277751 @default.
• W4361028650 cites W2114751173 @default.
• W4361028650 cites W2162541088 @default.
• W4361028650 doi "https://doi.org/10.2215/01.cjn.0000927088.58673.c3" @default.
• W4361028650 hasPublicationYear "2010" @default.
• W4361028650 type Work @default.
• W4361028650 citedByCount "0" @default.
• W4361028650 crossrefType "journal-article" @default.
• W4361028650 hasAuthorship W4361028650A5059400966 @default.
• W4361028650 hasAuthorship W4361028650A5061287999 @default.
• W4361028650 hasAuthorship W4361028650A5075099729 @default.
• W4361028650 hasAuthorship W4361028650A5085054297 @default.
• W4361028650 hasAuthorship W4361028650A5087164252 @default.
• W4361028650 hasBestOaLocation W43610286501 @default.
• W4361028650 hasConcept C120665830 @default.
• W4361028650 hasConcept C121332964 @default.
• W4361028650 hasConcept C126322002 @default.
• W4361028650 hasConcept C168563851 @default.
• W4361028650 hasConcept C177713679 @default.
• W4361028650 hasConcept C2778715236 @default.
• W4361028650 hasConcept C2779015954 @default.
• W4361028650 hasConcept C2779719350 @default.
• W4361028650 hasConcept C2780073493 @default.
• W4361028650 hasConcept C2780252810 @default.
• W4361028650 hasConcept C2780303639 @default.
• W4361028650 hasConcept C2781307858 @default.
• W4361028650 hasConcept C2909675724 @default.
• W4361028650 hasConcept C2911091166 @default.
• W4361028650 hasConcept C61511704 @default.
• W4361028650 hasConcept C71924100 @default.
• W4361028650 hasConceptScore W4361028650C120665830 @default.
• W4361028650 hasConceptScore W4361028650C121332964 @default.
• W4361028650 hasConceptScore W4361028650C126322002 @default.
• W4361028650 hasConceptScore W4361028650C168563851 @default.
• W4361028650 hasConceptScore W4361028650C177713679 @default.
• W4361028650 hasConceptScore W4361028650C2778715236 @default.
• W4361028650 hasConceptScore W4361028650C2779015954 @default.
• W4361028650 hasConceptScore W4361028650C2779719350 @default.
• W4361028650 hasConceptScore W4361028650C2780073493 @default.
• W4361028650 hasConceptScore W4361028650C2780252810 @default.
• W4361028650 hasConceptScore W4361028650C2780303639 @default.
• W4361028650 hasConceptScore W4361028650C2781307858 @default.
• W4361028650 hasConceptScore W4361028650C2909675724 @default.
• W4361028650 hasConceptScore W4361028650C2911091166 @default.
• W4361028650 hasConceptScore W4361028650C61511704 @default.
• W4361028650 hasConceptScore W4361028650C71924100 @default.
• W4361028650 hasIssue "2" @default.
• W4361028650 hasLocation W43610286501 @default.
• W4361028650 hasLocation W43610286502 @default.
• W4361028650 hasOpenAccess W4361028650 @default.
• W4361028650 hasPrimaryLocation W43610286501 @default.
• W4361028650 hasRelatedWork W1600771015 @default.
• W4361028650 hasRelatedWork W1964373005 @default.
• W4361028650 hasRelatedWork W2055223186 @default.
• W4361028650 hasRelatedWork W2065729608 @default.
• W4361028650 hasRelatedWork W2090961663 @default.
• W4361028650 hasRelatedWork W2151417740 @default.
• W4361028650 hasRelatedWork W2186819568 @default.
• W4361028650 hasRelatedWork W3085395330 @default.
• W4361028650 hasRelatedWork W4313252209 @default.
• W4361028650 hasRelatedWork W49922521 @default.
• W4361028650 hasVolume "5" @default.
• W4361028650 isParatext "false" @default.
• W4361028650 isRetracted "false" @default.
• W4361028650 workType "article" @default.